Latest Regulatory News

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Cedar Woods Properties Limited delivered a robust FY25 with a 19% increase in net profit, underpinned by a diversified project portfolio and favourable market conditions. The company signals continued growth with a 10% NPAT guidance for FY26, supported by strong presales and strategic partnerships.

AUB Group Limited has reported a robust FY25 financial performance, highlighted by a 171% increase in underlying net profit after tax and a 15.2% rise in total dividends. Strategic acquisitions and organic growth across divisions underpin the company’s strong momentum.

Genesis Energy reported a robust FY25 with a 14% rise in normalised EBITDAF and a 29% jump in net profit, driven by strategic portfolio flexibility amid volatile energy markets. The company accelerated its Gen35 strategy, including key renewable projects and long-term capacity contracts to bolster New Zealand’s energy security.

Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.

Unibail-Rodamco-Westfield has requested suspension of its securities from the ASX, marking the first step toward its official delisting. This move signals a significant shift for investors and the commercial property sector.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.